- Home
- ALPX vs SGMT Comparison
ALPX vs SGMT Comparison
Compare ALPX & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | ALPX | SGMT |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.3M | 169.4M |
| IPO Year | 2026 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ALPX | SGMT |
|---|---|---|
| Price | $9.95 | $11.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $26.13 |
| AVG Volume (30 Days) | 89.7K | ★ 1.3M |
| Earning Date | N/A | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.85 | $4.50 |
| 52 Week High | $9.97 | $11.15 |
Technical Indicators
Market Signals| Indicator | ALPX | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 65.25 | 68.95 |
| Support Level | $9.92 | $6.55 |
| Resistance Level | $9.97 | $11.15 |
| Average True Range (ATR) | 0.01 | 0.57 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 62.50 | 91.83 |
Price Performance
Historical ComparisonAbout ALPX Alpex Acquisition Corporation Class A Ordinary Shares
Alpex Acquisition Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.